Centre Hospitalier Valence — Clinical Trial Site

40 Registered trials

13 Currently recruiting

Organisation

Centre Hospitalier Valence

Location

Valence, France

Identifier

ORG-100042394

Address

179 Boulevard Marechal Juin, 26000, France

Departments

Département de dermatologie
dermatologie
Dermatology Department
gastro enterology
Gastro-Entérologie
Gastroentérologie
gastroenterology
Gastroenterology department
Head and neck surgery
Hématologie
hématologie et oncologie médicale
Hematology
Hepato Gastro-Entérologie
Hépato-Gastro-Entérologie
Hepato-gastroenterology
hepatogastroenterology
Maladies infectieuses
Medical oncology
Onco-Hematology
ONCOLOGIE
oncology
Service d' Hépato-Gastro-Entérologie
Service d'hématologie
Service d'hématologie oncologie
Service d'oncologie médicale
Service de dermatologie
Service de Pneumologie
Service Neurologie

Clinical trials at this site (40)

Search interface

Clinical trial of MK-7648A in adults and children with skin cancer Not authorised

2022-501417-31-00 High-risk Resected Melanoma 5
Comparison of azathioprine to methotrexate in combination therapy with adalimumab in Crohn’s Disease: an open-label randomized controlled tr… Pending

2024-514633-38-00 Crohn’s Disease 5
FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial Pending

2024-514964-24-00 ulcerative colitis 5
Efficacy of prophylactic levetiracetam for improving functional outcome in the acute phase of intracerebral haemorrhage: a randomised, doub… Pending

2024-515663-59-00 intracerebral haemorrhage 5
Efficacy of an empirical treatment with Amoxicillin-clavulanate (AC) compared to the combination Amoxicillin-clavulanate and Ciprofloxacin (… Pending

2025-520995-24-00 Adult patients treated for haematological disorders, in 5
Study PACIFIC: Fixed duration treatment with combined pirtobrutinib and short course immuno-chemotherapy in fit patients with previously unt… Pending

2025-521199-80-00 Patients with previously untreated symptomatic chronic 4
Evaluation of the efficacy of corticosteroids in septic arthritis in adults: Randomized double-blind controlled trial [CORSAR] Pending

2025-522193-37-00 Septic arthritis 5
Phase 3 study comparing ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and… Recruiting

2025-522996-27-00 recurrent and/or metastatic squamous cell carcinoma of 5 2026-05-05
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Patients with HR+ HER2- early breast cancer at intermed 5 2025-12-18
A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with a… Recruiting

2023-509606-30-00 Ulcerative colitis 5 2024-07-24
PRODIGE 115 (FFCD 2406) ULYSSE : FOLFOX/FOLFIRI + Bévacizumab ou Fruquintinib en 2ème ligne du Cancer Colorectal métastatique (CCRm) : essai… Recruiting

2025-522108-26-00 métastatique colorectal cancer 4 2026-02-19
Trial of Tepotinib compared to Standard Treatment in Patients with Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer Recruiting

2024-519971-25-00 Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer 5 2025-12-03
Testing ivonescimab versus FOLFOX in advanced biliary tract cancer patients Recruiting

2024-515875-36-00 Advanced biliary tract cancer (BTC) 4 2025-08-18
PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting

2024-515297-27-00 colon carcinoma 5 2024-08-14
SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVa… Recruiting

2023-508260-30-01 Patients with poor prognostic OVARian cancers based on 5 2024-07-30
Personalized medicine for advanced biliary cancer patients Recruiting

2023-508100-38-00 Advanced Biliary Cancer (ABC) 5 2024-06-24
Comparison of Vedolizumab treatment to Adalimumab dose intensification in Crohn’s disease patients with loss of response or biomarker activi… Recruiting

2023-508154-25-00 Crohn's disease 6 2024-05-27
Evaluation of EXL01 a new Live Biotherapeutic Product to prevent recurrence of Clostridioides difficile infection in high-risk patients. LIV… Recruiting

2023-506232-32-00 Multiple recurrences of Clostridioides difficile infect 9 2024-04-08
A randomized phase I/ II multicenter study evaluating combination of luspatercept in LR-MDS without RS having failed or being ineligible to … Recruiting

2024-515354-24-00 Low risk myelodysplastic syndrom without RS having fail 9 2022-05-18
Evaluation of an initial treatment with bevacizumab in combination with chemotherapy and then in combination with niraparib in maintenance i… Recruiting

2023-504166-37-00 Advanced ovarian, tubal or peritoneal cancer. 4 2022-02-01
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended

2023-508636-61-00 Crohn’s Disease 5 2024-10-24
PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed… Ended

2023-505972-32-00 locally advanced anal squamous cell carcinoma 5 2024-02-26
Study of safety and efficacy of ONUREG in combination with VENETOCLAX in higher-risk myelodysplastic syndromes ineligible for allogenic tran… Ended

2024-514876-41-00 Higher-risk myelodysplastic syndromes untreated and ine 9 2023-12-06
A Study to Evaluate Atezolizumab and Bevacizumab, with and without Tiragolumab, In Patients With Untreated Locally Advanced or Metastatic He… Ended

2023-503422-39-00 Hepatocellular Carcinoma (HCC) 5 2023-10-20